Europe Drug Delivery Market, By Product Type (Oral Drug Delivery, Pulmonary Drug Delivery, Injectable Drug Delivery, Opthalmic Drug Delivery, Nasal Drug Delivery, Topical Drug Delivery, Implantable Drug Delivery, Transmucosal Drug Delivery), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2030.
Europe Drug Delivery Market Analysis and Size
The rise in chronic and infectious diseases is one of the major drivers of the European drug delivery market. Infectious diseases have observed a sudden outbreak and are developing at a rate never seen before in the last 5-6 decades. The growth of drug delivery market has increased with growing acceptance of self-administering drugs and awareness about diagnosis and treatment in developed and developing countries. Additionally, the increasing incidence of cardiovascular diseases has become a cause of major public health concern.
Data Bridge Market Research analyses a growth rate in the drug delivery market in the forecast period 2023-2030. The expected CAGR of drug delivery market is tend to be around 7.7% in the mentioned forecast period. The market is valued at USD 391.2 million in 2022, and it would grow upto USD 708.15 million by 2030. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Europe Drug Delivery Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Product Type (Oral Drug Delivery, Pulmonary Drug Delivery, Injectable Drug Delivery, Opthalmic Drug Delivery, Nasal Drug Delivery, Topical Drug Delivery, Implantable Drug Delivery, Transmucosal Drug Delivery), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe
|
|
Market Players Covered
|
Nemera (France), F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), AstraZeneca (U.K.), Johnson & Johnson Private Limited (U.S.), Merck & Co., Inc. (U.S.), 3M (U.S.), Bayer AG (Germany), Takeda Pharmaceutical Company Limited (Japan)
|
|
Market Opportunities
|
|
Market Definition
Drug delivery is the process of introducing a therapeutic effect in the body of human by administering a drug at a specific targeted site. The safety and efficacy of drug can be improved by controlling the rate, time and release of drug in the body. There can be several ways of delivering drugs such as oral, pulmonary, nasal, injectable, and others. The drug delivery systems are advanced by studying and developing the properties of nanoparticles, which have made the drug delivery process more efficient and time-saving.
Europe Drug Delivery Market Dynamics
Drivers
- Increasing Product Developments
Various product developments are started by numerous companies worlwide which are also increasing the growth of market. For instance, Janssen Pharmaceutical Companies of Johnson & Johnson Services, Inc. in February 2020 told about submitting a supplemental Biologics License Application (sBLA) to the U.S. FDA of DARZALEX combined with Kyprolis and dexamethasone which is used for the treatment of relapsed or refractory multiple myeloma. This as a result, increases the demand for the market.
- Rising Cases of Cardiovascular Diseases
The growing occurrence of cardiovascular diseases (CVDs) has become a major public health concern. CVDs are primarily responsible for approximately 46% of the total mortality rate in the country. Injectable drug delivery technology has developed as a source of relief for the elderly and CVD patients since they help provide a better quality of life. This factor is boosting the growth of the KSA injectable drug delivery market during the forecast period 2023-2029. Thus, this factor increases the market growth.
Opportunities
- Increasing Preference Towards Feasible Routes of Administration
One of the developing trends in the topical drug delivery market is the delivery of biologics through the transdermal route. The wide use of transdermal delivery of big molecules provides significant patient benefits such as painless medication delivery and cost-effective treatment. This factor is expected to increase the growth of the market. Additionally, the preference towards administration of drugs through the skin to control or extend drug delivery and the use of this process as a substitute to the oral route are also projected to boost market growth.
- Increasing Demand For Rising Cancer Cases
According to Cancer Research UK 2018, the population suffering from cancer is projected to surge in the future. As per the report, if the current trends in the occurrence of major cancers and population growth are persistent, it is expected there will be 27.5 million new cancer cases worldwide every year by 2040, more than 17 million in 2018. Furthermore, in European regions such as the UK there is also an increase in incident cases of cancer, as per Cancer Research UK's 2019 report. Thus, this factor increases the market growth.
Restraints/Challenges
- Increased Expenditure of Treatment
The high expenditure related with drug delivery and the huge cost required to conduct the assays hinder the market growth. The increased cost associated with the manufacturing, supply and drug delivery is often not possible for the developing and underdeveloped countries, cause the under treatment of numerous patients. This impedes the market growth.
This drug delivery market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the drug delivery market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Recent Development
- In 2020, Bayer AG completed the submission of application for the U.S. approval of nifurtimox, which is a drug for treating pediatric patients with Chagas disease. This will fix the condition of children suffering from this disease and also benefit the company as it is a novel formulation for children and revenue generation will be increased for the organization.
- In 2019, F. Hoffmann-La Roche Ltd completed the acquisition of Spark Therapeutics, Inc. Spark is an organization that is dedicated to investigational gene therapy. This will open several opportunities for Roche and also will lead to more revenues.
Europe Drug Delivery Market Scope
The drug delivery market is segmented on the basis of product type, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Product Type
- Oral Drug Delivery
- Pulmonary Drug Delivery
- Injectable Drug Delivery
- Opthalmic Drug Delivery
- Nasal Drug Delivery
- Topical Drug Delivery
- Implantable Drug Delivery
- Transmucosal Drug Delivery
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Drug Delivery Market Regional Analysis/Insights
The drug delivery market is analyzed and market size insights and trends are provided by product type, end user, and distribution channel as referenced above.
The major countries covered in the drug delivery market report are Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe.
Europe leads the market because of the increase in the adoption rate of numerous new technological advancements in the drug delivery. Also, the surge in elderly population and the rise in disposable income of the people within the region increases the market growth.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Europe Drug Delivery Market Share Analysis
The drug delivery market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, Europe presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to drug delivery market
Key players operating in the drug delivery market include:
- Nemera (France)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- AstraZeneca (U.K.)
- Johnson & Johnson Private Limited (U.S.)
- Merck & Co., Inc. (U.S.)
- 3M (U.S.)
- Bayer AG (Germany)
- Takeda Pharmaceutical Company Limited (Japan)
SKU-